Everything about medications
Strategic Acquisition Opportunity
Leading Pharmaceutical Information Platform in Uruguay & Paraguay
Monopolistic Pharma Data Asset in LATAM
Farmanuario is Uruguay's dominant pharmaceutical information platform with 35+ years of operation, a proprietary pharmacological database, and active government contracts. A unique hybrid model combining advertising (70%), IT products (22%), and publications (8%) creates resilient, multi-stream revenue. Digital IT products grew 87% in 2022-2023.
35+
Years in Business
Founded 1988
17
Employees
Lean team, 3rd party dev
Monopolistic in Uruguay
Only comprehensive pharmaceutical database in Uruguay. Declared of Ministerial Interest in 2019 for 30+ years of objective technical information.
Digital-First Growth Engine
IT products grew from 13% to 22% of revenue (2022-2023). Farmanuario WEB already operates as SaaS. Recently invested USD 15K in platform modernization (Java to modern stack).
Government Contracts
Active agreements: National Drug Dictionary (Uruguay since 2015), World Bank-funded project in Argentina (2023). USD 108K+ annual recurring government revenue.
Scalable Without Headcount
Digital platform can scale to other countries. 50-70% of technical database is reusable internationally. Development outsourced, 15+ year stable relationship.
Strategic Assets, Not Just a Business
This is a proprietary data platform with 30+ years of accumulated intellectual property, institutional relationships, and market dominance.
Proprietary IP & Pharmacological Database
30+ years of curated pharmaceutical data, drug interactions, dosing protocols, and clinical references. The core strategic asset.
Updated Commercial Database
Continuously maintained product catalog covering all commercialized pharmaceuticals in Uruguay and Paraguay.
International Scientific Committee
Network of medical and pharmaceutical experts providing ongoing content validation and updates.
Leading Brand in Uruguay
The recognized standard for pharmaceutical information among healthcare professionals nationwide.
Pharmaceutical Industry Relationships
Deep relationships with major pharmaceutical companies for advertising, content, and data partnerships.
Active Government Contracts
Current agreements with AGESIC, ASSE, and proven track record with World Bank projects in Argentina.
Integrable Digital Platform (SIM)
Cloud-based system with API/Webservice capabilities, mobile apps, and web SaaS ready for enterprise integration.
10,000+ Subscriber Community
Established base of healthcare professionals actively using and paying for platform access.
Three Revenue Engines
Advertising remains the stable core (70%), while IT products are the growth engine (+87% in 2022-2023). Publications provide legacy stability. The mix is shifting toward higher-margin digital.
Advertising
High-margin, dollarized revenue from pharmaceutical companies in book and digital products
- Pharmaceutical company placements
- Book + digital ad inventory
- Premium positioning packages
- Dollarized contracts (USD)
- Quasi-recurrent annual renewals
IT Products
Fastest growing line: SaaS, mobile apps, corporate APIs, government contracts
- Farmanuario WEB (SaaS)
- Farmanuario Mobile App
- Corporate API integrations
- National Drug Dictionary contracts
- High margins, recurring once sold
Publications
Book sales and medical journals. Legacy but stable with niche demand
- Farmanuario Book (annual)
- Tendencias en Medicina (medical)
- Hola Salud (pharmacy)
- Publishing custom materials
- Distribution network established
One Core Asset, Multiple Digital Channels
Proprietary Pharmaceutical Knowledge Graph
35+ years of proprietary pharmacological data. 2,000+ original medical articles. International Scientific Committee. 50-70% reusable across countries.
Farmanuario Book
Annual pharmacological guide. 35 years, still monopolistic in Uruguay
Mobile App
iOS/Android with offline access, weekly cloud updates, drug search & interactions
Farmanuario WEB
SaaS platform for individual and corporate licenses. Already integrated with EHRs
Corporate API
Web services for hospitals, pharmacies. Deployed at Scanntech (UY), Argentine EHRs
Government DBs
National Drug Dictionary (UY since 2015, AR 2023). IDB/World Bank funded
Medical Publications (Advertising + Subscriptions)
Tendencias en Medicina
Leading medical journal in UY & PY. Peer-reviewed, indexed in LATINDEX
Hola Salud
Pharmacy magazine. Monthly distribution to all pharmacies, free + subscriptions
This is a data platform, not a book. The book is one channel. Digital products (WEB, App, API) are the growth engine.
Dominant Position in Key Markets
#1
Monopolistic in Uruguay
No direct competitor
2023
World Bank Validation
Argentina project winner
3
Active / Pipeline Markets
UY, PY, AR
Uruguay
Monopolistic position as the only comprehensive pharmaceutical data provider.
- Only pharma info platform in market
- Government-validated data source
- 100% healthcare professional awareness
- Active AGESIC & ASSE contracts
Paraguay
Established market leader with growing institutional adoption.
- Leading pharmaceutical reference
- Growing subscriber base
- Institutional partnerships
- Distribution infrastructure in place
Argentina
Proven track record with World Bank project. Pipeline for re-entry.
- World Bank contract winner (2023)
- Prior market presence established
- 10x market size vs Uruguay
- Re-entry strategy defined
Three Structural Barriers to Entry
Farmanuario's competitive position is defended by structural advantages that cannot be easily replicated, creating a durable moat for long-term value.
Proprietary Technical Database (30+ Years)
Three decades of curated pharmacological data, drug interactions, dosing protocols, and clinical references. This dataset cannot be replicated without equivalent time and domain expertise.
vs. Competitors: No competitor has attempted to build an equivalent database in Uruguay or Paraguay.
Institutional Integration & Government Validation
Active contracts with AGESIC, ASSE, and validation through World Bank Argentina project. Deep integration into public health infrastructure creates switching costs.
vs. Competitors: Competitors lack institutional credibility and government-level contract history.
Trusted Brand at Point of Prescription
Healthcare professionals rely on Farmanuario at the moment of clinical decision-making. 30+ years of trust at the most critical touchpoint in pharmaceutical information.
vs. Competitors: New entrants would need decades to build equivalent professional trust.
Highest-value pharmaceutical information asset in Uruguay with structural moats that competitors cannot replicate.
The Fastest Growing Line: IT Products
IT products grew from 13% to 22% of revenue (2022-2023), and are projected to reach 29% by 2026. The digital platform can scale without proportionally increasing headcount.
Print Foundation
Farmanuario book launched, became monopolistic by 1990 after government publication ceased
Digital Expansion
Farmanuario PC software, web platform, mobile app. Won National Drug Dictionary contract (2014)
SaaS & API Scale
Platform modernized (Java to modern stack). API integrations, regional SaaS potential, AI/LLM opportunities
Digital Products & Growth Potential
Farmanuario Mobile
Native iOS/Android app with offline access, weekly cloud updates, ad placements per drug
Farmanuario WEB
SaaS platform for individual and corporate licenses. Integrates with EHR, pharmacy management, e-prescribing
Corporate API
Web services for hospitals and pharmacy chains. Already deployed at Scanntech (UY) and Argentine EHR vendors
AI/LLM Ready
Proprietary local drug data not available in public AI models. Opportunity for chatbots and clinical decision support
Strategic Growth Levers
Six growth strategies validated by General Director insights. Focus: digital products first (fastest ROI), then regional expansion with proper commercial resources.
Scale IT Products (Fastest ROI)
IT products already growing fastest (22% of revenue, +87% growth). Farmanuario WEB is SaaS-ready. Push e-prescribing and EHR integrations in Uruguay and Paraguay.
"IT products are recurring and have high margins once sold."
Argentina Re-entry
World Bank contract (2023) positions Farmanuario for re-entry. Currency flow issues were the barrier before. Chile also high priority with easier operations.
"Argentina and Chile are the easiest expansions operationally."
API & Data Licensing
Already have agreements with Scanntech (UY) and Argentine EHR vendors. Robust API ready for multi-integration. Per-query or flat licensing models.
"No limits on integration. We already provide technical support."
AI/LLM Data Monetization
Public AI lacks local drug data with brands and presentations. Farmanuario data is unique for chatbots and clinical decision support in LATAM markets.
"AI only handles public info. We have proprietary local product data."
Government Database Contracts
Replicate National Drug Dictionary model (Uruguay, Argentina) in other LATAM countries. IDB/World Bank-funded projects are a proven pathway.
"Same multilateral organizations could convene us for other countries."
Commercial Team Expansion
Main barrier is commercial resources, not technology. Investment in sales teams and local gerencia can unlock growth in current and new markets.
"We are conservative in hiring. With stronger commercial teams, we could be more aggressive."
Transaction Structure
Asset purchase or share acquisition
IP & database transfer terms
Scientific committee continuity
Key team retention agreements
Government contract transferability
Working capital requirements
Digital platform migration plan
Expansion rights & pipeline transfer
Due Diligence Focus Areas
Financial
- Historical revenue & profitability (2022-2025)
- Working capital & cash flow analysis
- Digital vs. print revenue split
- Advertising revenue metrics
- Product-level profitability
Commercial
- Market share & positioning data
- Subscriber base & growth metrics
- Institutional client contracts
- Brand valuation & awareness
- Advertising client retention
Operational
- Content update processes & cadence
- Technology infrastructure & stack
- Scientific committee structure
- Editorial workflow & quality systems
- Digital platform capabilities
Regulatory & Legal
- IP ownership & protection
- Government contract terms
- Data licensing agreements
- Employment compliance
- Litigation history & disputes
Strategic
- Expansion plan execution timeline
- Argentina re-entry feasibility
- Digital transformation roadmap
- Key personnel retention plan
- AI & data product potential
The Timing Advantage
Post-COVID recovery, digital product momentum, and management transition readiness create an optimal entry window.
Post-COVID Recovery Momentum
2024 projected at USD 1.67M (+22% YoY) with 34% EBITDA margin. The company is returning to 2019 performance levels after pandemic impact. Optimal entry point before full recovery is priced in.
AI/LLM Data Opportunity
Public AI lacks local drug data with brands and presentations. Farmanuario's proprietary database is unique for chatbots, clinical decision support, and LLM applications in LATAM healthcare.
Management Transition Ready
Founders (35+ years experience) available for transition. Main barrier has been commercial resources, not technology. A buyer with sales muscle can unlock immediate growth.
Tech Buyer
Transform into regional SaaS platform. Scale API monetization. Build AI products on proprietary data.
Commercial Buyer
Expand to Argentina, Chile, Colombia with strong sales teams. Current barrier is HR, not tech.
Key Enablers
Experienced Operational Structure with Transition Underway
Farmanuario has evolved from a founder-led business into a progressively institutionalized organization with specialized operational leadership across key functions.
Luis
Director
Strategy and institutional relationships
Griselda
Director
Head of Sales
CFO
Finance, administration & operational management
Head of Office
Office operations & coordination
Head of Production
Editorial & publishing workflows
Head of Marketing
Brand, communications & growth
Key insight: Operational knowledge is increasingly distributed across specialized functions, reducing single points of failure.
Leadership Transition Already Underway
Farmanuario has initiated a gradual transition process designed to strengthen operational continuity and reduce founder dependency over time.
Founder-Centric
1988-2020
Core knowledge concentrated with founders
Structured Delegation
2020-2024
Progressive function specialization
Institutional Model
2025+
Fully transferable operational structure
"Continuity and operational transferability are strategic priorities for the organization."
The Data Platform Behind LATAM Pharma
30+ years of pharmaceutical intelligence. Ready for the next chapter.
For inquiries regarding this acquisition opportunity, please contact our transaction representative.
martinlarre@gmail.com